Deans' stroke musings: Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, October 23, 2018

Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice

I don't want best clinical practice, that is just laziness. I want a protocol. For this objective starting point ; these exact interventions need to occur. Nothing should be left to chance and interpretation. But that is just my non-medical understanding. Prove me wrong and I can change my position.

Registration and Dinner: 6:30-7 p.m.
Symposium: 7-9 p.m., Sunday, Nov. 11
InterContinental Chicago Grand Ballroom, 7th Floor
Sponsor: Voxmedia - Supporter: Amgen

Program Overview: Nonstatin drugs (ezetimibe, PCSK9 inhibitors) further lower LDL-C and further reduce cardiovascular risk when added to statins, while demonstrating safety at low LDL-C levels.

MORE